Jennifer Kherani

1.5k total citations
19 papers, 241 citations indexed

About

Jennifer Kherani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Jennifer Kherani has authored 19 papers receiving a total of 241 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Jennifer Kherani's work include Lung Cancer Treatments and Mutations (8 papers), Thyroid Cancer Diagnosis and Treatment (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jennifer Kherani is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Thyroid Cancer Diagnosis and Treatment (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jennifer Kherani collaborates with scholars based in United States, Singapore and Australia. Jennifer Kherani's co-authors include Elizabeth Olek, Lori J. Wirth, Alexander Drilon, Thomas J. Povsic, Enrikas Vainorius, Pascal J. Goldschmidt‐Clermont, Eric D. Peterson, S. Michael Rothenberg, Caroline E. McCoach and Matthias Scheffler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jennifer Kherani

18 papers receiving 235 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer Kherani United States 10 113 104 65 54 45 19 241
Duc Le Canada 10 153 1.4× 97 0.9× 67 1.0× 30 0.6× 37 0.8× 26 308
Xuyou Zhu China 10 110 1.0× 137 1.3× 93 1.4× 30 0.6× 43 1.0× 34 314
И. С. Стилиди Russia 12 111 1.0× 145 1.4× 105 1.6× 28 0.5× 96 2.1× 103 372
Igor Djurisic Serbia 10 90 0.8× 60 0.6× 75 1.2× 91 1.7× 73 1.6× 31 325
Guilherme Harada Brazil 11 155 1.4× 161 1.5× 90 1.4× 16 0.3× 66 1.5× 40 317
Gordana Pupić Serbia 10 91 0.8× 49 0.5× 79 1.2× 98 1.8× 79 1.8× 32 325
Crystal Hilger United States 10 146 1.3× 60 0.6× 33 0.5× 208 3.9× 31 0.7× 13 336
Corinne Clifford United States 10 202 1.8× 214 2.1× 91 1.4× 55 1.0× 113 2.5× 14 348
Minghan Jia China 10 206 1.8× 102 1.0× 133 2.0× 23 0.4× 127 2.8× 21 394
Beili Gao China 10 135 1.2× 106 1.0× 122 1.9× 19 0.4× 42 0.9× 24 278

Countries citing papers authored by Jennifer Kherani

Since Specialization
Citations

This map shows the geographic impact of Jennifer Kherani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Kherani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Kherani more than expected).

Fields of papers citing papers by Jennifer Kherani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Kherani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Kherani. The network helps show where Jennifer Kherani may publish in the future.

Co-authorship network of co-authors of Jennifer Kherani

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Kherani. A scholar is included among the top collaborators of Jennifer Kherani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Kherani. Jennifer Kherani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Rotow, Julia, Jyoti D. Patel, Helena A. Yu, et al.. (2023). Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR -Mutant and RET Fusion-Positive Lung Cancers. Clinical Cancer Research. 29(16). 2979–2987. 26 indexed citations
2.
Yu, Wenhui, Jennifer Kherani, Lili Zhao, et al.. (2023). OC 54.3 Direct Oral Anticoagulants vs Low Molecular Weight Heparin in the Management of Patients with Primary or Metastatic Brain Tumours: A Systematic Review and Meta-Analysis. Research and Practice in Thrombosis and Haemostasis. 7. 100594–100594.
3.
4.
Wickremsinhe, Enaksha, Erwin Berthier, Diego López de Castilla, et al.. (2022). Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver Chemistry. The Journal of Applied Laboratory Medicine. 8(3). 535–550. 35 indexed citations
5.
McCoach, Caroline E., Christian Rolfo, Alexander Drilon, et al.. (2022). Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001. Journal of Thoracic Oncology. 17(6). 768–778. 27 indexed citations
6.
Wirth, Lori J., Eric J. Sherman, Bruce Robinson, et al.. (2021). O10-3 Selpercatinib (LOXO-292) in patients (pts) with RET-altered thyroid cancer. Annals of Oncology. 32. S289–S289. 1 indexed citations
7.
Wirth, Lori J., Bruce Robinson, Valentina Boni, et al.. (2021). Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial. The Oncologist. 27(1). 13–21. 14 indexed citations
8.
Minchom, Anna, Aaron C. Tan, Erminia Massarelli, et al.. (2021). Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial. The Oncologist. 27(1). 22–29. 6 indexed citations
9.
Rotow, Julia, Jyoti D. Patel, Helena A. Yu, et al.. (2021). FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions. Journal of Thoracic Oncology. 16(3). S230–S230. 20 indexed citations
10.
Watanabe, Satomi, Masayuki Takeda, Tomoyuki Otani, et al.. (2021). Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer. JCO Precision Oncology. 5(5). 103–106. 10 indexed citations
11.
12.
Dias‐Santagata, Dora, Jochen K. Lennerz, Peter M. Sadow, et al.. (2020). Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. Thyroid. 30(9). 1384–1389. 33 indexed citations
13.
McCoach, Caroline E., Benjamin Besse, Keiko Goto, et al.. (2020). 1291P Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI). Annals of Oncology. 31. S835–S836. 6 indexed citations
14.
Shah, Manisha H., Ye Zhou, Joshua D. Palmer, et al.. (2020). Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid. Clinical Lung Cancer. 22(3). e442–e445. 6 indexed citations
15.
Takeda, Masayuki, et al.. (2020). Abstract 5236: Complete response to selpercatinib (LOXO-292), a highly selective RET inhibitor, in a patient with RET fusion-positive breast cancer. Cancer Research. 80(16_Supplement). 5236–5236. 1 indexed citations
16.
Wirth, Lori J., Bruce Robinson, Valentina Boni, et al.. (2020). 1922P Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292). Annals of Oncology. 31. S1089–S1089. 2 indexed citations
17.
Shah, Manisha H., Eric J. Sherman, Bruce Robinson, et al.. (2020). Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.. Journal of Clinical Oncology. 38(15_suppl). 3594–3594. 11 indexed citations
18.
Leeman, Kristen T., et al.. (2016). Emergency Radiology “Boot Camp”: Educating Emergency Medicine Residents Using E‐learning Radiology Modules. AEM Education and Training. 1(1). 43–47. 11 indexed citations
19.
Povsic, Thomas J., et al.. (2008). Common endothelial progenitor cell assays identify discrete endothelial progenitor cell populations. American Heart Journal. 157(2). 335–344. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Duc Le Breakdown of academic impact, for papers by Xuyou Zhu Breakdown of academic impact, for papers by И. С. Стилиди Breakdown of academic impact, for papers by Igor Djurisic Breakdown of academic impact, for papers by Guilherme Harada Breakdown of academic impact, for papers by Gordana Pupić Breakdown of academic impact, for papers by Crystal Hilger Breakdown of academic impact, for papers by Corinne Clifford Breakdown of academic impact, for papers by Minghan Jia Breakdown of academic impact, for papers by Beili Gao
Rankless by CCL
2026